Cost Effectiveness of Hepatocellular Carcinoma Surveillance  After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis

Hepatitis C virus (HCV)-related cirrhosis increases the risk for hepatocellular carcinoma (HCC). After a sustained virologic response (SVR) to anti-HCV therapy, the risk of HCC is reduced but not eliminated. Recent developments in antiviral therapy have increased rates of SVR markedly. Guidelines recommend indefinite biannual ultrasound surveillance after SVR for patients with advanced fibrosis before treatment. Surveillance for HCC is cost effective before anti-HCV treatment; we investigated whether it remains so after SVR.

Source: Clinical Gastroenterology and Hepatology - December 19, 2018 Category: Gastroenterology Authors: Hooman Farhang Zangneh, William W.L. Wong, Beate Sander, Chaim M. Bell, Khalid Mumtaz, Matthew Kowgier, Adriaan J. van der Meer, Sean P. Cleary, Harry L.A. Janssen, Kelvin K.W. Chan, Jordan J. Feld Source Type: research